Martha Q. Lacy

Active 1996–2025

262
Papers
41,115
Citations
110
h-index
260
i10-index

Citations

Citations per year for Martha Q. Lacy1994: 1 citations1996: 4 citations1997: 21 citations1998: 24 citations1999: 36 citations2000: 30 citations2001: 54 citations2002: 61 citations2003: 114 citations2004: 178 citations2005: 166 citations2006: 193 citations2007: 283 citations2008: 222 citations2009: 287 citations2010: 308 citations2011: 315 citations2012: 333 citations2013: 373 citations2014: 384 citations2015: 332 citations2016: 417 citations2017: 310 citations2018: 326 citations2019: 1,079 citations2020: 1,234 citations2021: 1,079 citations2022: 796 citations2023: 501 citations2024: 847 citations2025: 369 citations2026: 5 citations1995: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,084 citing papers, 30.5% of this breakdownItaly: 758 citing papers, 7.5% of this breakdownUnited Kingdom: 619 citing papers, 6.1% of this breakdownGermany: 576 citing papers, 5.7% of this breakdownFrance: 531 citing papers, 5.3% of this breakdownChina: 473 citing papers, 4.7% of this breakdownSpain: 438 citing papers, 4.3% of this breakdownCanada: 332 citing papers, 3.3% of this breakdownNetherlands: 310 citing papers, 3.1% of this breakdownGreece: 307 citing papers, 3% of this breakdownAustralia: 245 citing papers, 2.4% of this breakdownJapan: 206 citing papers, 2% of this breakdown
0%30.5%Other 22.1%

Fields

  • Medicine64.9%
  • Biochemistry, Genetics and Molecular Biology29.4%
  • Immunology and Microbiology3.1%
  • Health Professions0.9%
  • Computer Science0.3%
  • Engineering0.3%
  • Other1.1%

Topics

  • Multiple Myeloma Research and Treatments18%
  • Protein Degradation and Inhibitors7.4%
  • Amyloidosis: Diagnosis, Treatment, Outcomes6.9%
  • Peptidase Inhibition and Analysis4.4%
  • Cancer Treatment and Pharmacology2.6%
  • Chronic Lymphocytic Leukemia Research2.4%
  • Other58.3%

Coauthors

All papers

Open in search
  1. Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements

    Authors: , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2012 cited by 1,124

  2. Review of 1027 Patients With Newly Diagnosed Multiple Myeloma

    Authors: , , , , , , , , , , , , - Mayo Clinic Proceedings 2003 cited by 2,431

  3. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients

    Authors: , , , , , , , , , , , , , , , - Leukemia 2013 cited by 1,396

  4. Serum Cardiac Troponins and N-Terminal Pro-Brain Natriuretic Peptide: A Staging System for Primary Systemic Amyloidosis

    Authors: , , , , , , , , , , , , , - Journal of Clinical Oncology 2004 cited by 973

  5. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Blood Cancer Journal 2018 cited by 289

  6. Improved survival in multiple myeloma and the impact of novel therapies

    Authors: , , , , , , , , , , , , - Blood 2007 cited by 2,251

  7. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2013 cited by 799

  8. Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline

    Authors: , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2019 cited by 333

  9. Natural history, predictors of development of extramedullary disease, and treatment outcomes for patients with extramedullary multiple myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , - American Journal of Hematology 2023 cited by 53

  10. A simple additive staging system for newly diagnosed multiple myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Blood Cancer Journal 2022 cited by 95

  11. Mortality trends in multiple myeloma after the introduction of novel therapies in the United States

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Leukemia 2021 cited by 102

  12. IAP antagonists induce anti-tumor immunity in multiple myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Medicine 2016 cited by 171

  13. Clinical Course of Patients With Relapsed Multiple Myeloma

    Authors: , , , , , , , , , , , - Mayo Clinic Proceedings 2004 cited by 365

  14. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Blood 2014 cited by 384

  15. Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Blood 2017 cited by 342

  16. Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Blood Advances 2020 cited by 95

  17. A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry–Verified Typing

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Mayo Clinic Proceedings 2019 cited by 129

  18. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , C Anderson Kenneth, Michael Attal, Hervé Avet‐Loiseau, Ashraf Badros, Dalsu Baris, Bart Barlogie, Régis Bataille, Meral Beksaç, Andrew Belch, Dina Ben‐Yehuda, Bill Bensinger, P. Leif Bergsagel, Jenny Bird, Joan Bladé, Mario Boccadoro, Michèle Cavo, Asher Chanan‐Khan, Wen Ming Chen, Tony Child, James Chim, Wee Joo Chng, Ray Comenzo, John Crowley, William S. Dalton, Faith E. Davies, Cármino Antônio De Souza, Michel Delforge, Meletios Α. Dimopoulos, Angela Dispenzieri, Johannes Drach, Matthew T. Drake, Brian G.M. Durie, Hermann Einsele, Theirry Facon, Dorotea Fantl, Jean‐Paul Fermand, Rafaël Fonseca, Gösta Gahrton, Ramón García‐Sánz, Christina Gasparetto, Morie A. Gertz, John Gibson, Sergio Giralt, Hartmut Goldschmidt, Philip R. Greipp, Roman Hájek, Izhar Hardan, Parameswaran Hari, Jean‐Luc Harousseau, Hiroyuki Hata, Yutaka Hattori, Tom Heffner, Joy Ho, Vânia Hungria, Shinsuke Ida, Peter Jacob, Sundar Jagannath, Hans Erik Johnsen, Jian Hou, Douglas Joshua, Artur Jurczyszyn, Michio Kawano, Nicolaus Kröger, Shaji Kumar, Robert A. Kyle, Martha Q. Lacy, Juan José Lahuerta, Ola Landgren, Jacob P. Laubach, Jae Hoon Lee and 60 more - Leukemia 2011 cited by 721

  19. Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Mayo Clinic Proceedings 2013 cited by 495

  20. Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma

    Authors: , , , , , , , - Blood Cancer Journal 2013 cited by 137

  21. Clinical Activity of Single Dose Systemic Oncolytic VSV Virotherapy in Patients with Relapsed Refractory T-Cell Lymphoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Taxiarchis Kourelis, Eli Muchtar, Prashant Kapoor, Robert A. Kyle, Yi Lin, Mustaqeem Siddiqui, Amie Fonder, Miriam Hobbs, Yi L. Hwa, Shruthi Naik, Stephen J. Russell, Martha Q. Lacy - Blood Advances 2022 cited by 43

  22. Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Leukemia 2018 cited by 128

  23. The clinical significance of cereblon expression in multiple myeloma

    Authors: , , , , , , , , , , , , , , , , , , - Leukemia Research 2013 cited by 109

  24. Reduction in C‐reactive protein indicates successful targeting of the IL‐1/IL‐6 axis resulting in improved survival in early stage multiple myeloma

    Authors: , , , , , , - American Journal of Hematology 2016 cited by 92